Showing 4571-4580 of 5771 results for "".
- Clearside Biomedical Expands Patent Portfolio in the US and Europehttps://modernod.com/news/clearside-biomedical-expands-patent-portfolio-in-the-us-and-europe/2478203/Clearside Biomedical announced the recent issuance of three additional patents in the United States and Europe. The United States Patent and Trademark Office (USPTO) recently granted patent number 10,722,396 to Clearside. This patent covers Clearside’s SCS M
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- ForwardVue Pharma Secures Funding to Advance Preclinical Development Programshttps://modernod.com/news/forwardvue-pharma-secures-funding-to-advance-preclinical-development-programs/2478206/ForwardVue Pharma has secured initial seed round funding in order to advance preclinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. Based on this progress, ForwardVue has announced a ne
- FDA Approves Cystadrops for the Ocular Manifestations of Cystinosishttps://modernod.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/Recordati Rare Diseases announced the FDA has approved Cystadrops (cysteamine ophthalmic solution 0.37%), a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. Cystadrops demonstrated a significant reduction in cystine crystal deposits i
- SIFI Reports Positive Results From 044/si Phase 3 Clinical Trial of Netildex Gelhttps://modernod.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/SIFI has announced the conclusion of a phase 3 clinical trial aimed at demonstrating the noninferiority of Netildex gel administered twice daily (BID) vs. Netildex solution administered four ti
- Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-completes-enrollment-in-phase-2-clinical-trial-for-dry-eye-disease/2478192/Neuroptika announced completion of enrollment in a phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease. NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases. “We are pleased to com
- FDA Grants EUA for Convalescent Plasma in Hospitalized COVID-19 Patientshttps://modernod.com/news/fda-grants-eua-for-convalescent-plasma-in-hospitalized-covid-19-patients/2478190/The FDA reversed itself Sunday following pressure from the White House and announced an Emergency Use Authorization for convalescent plasma as a treatment for patients who have contracted COVID-19, according to a BioSpace
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- LensGen Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directorshttps://modernod.com/news/lensgen-closes-10-million-financing-and-welcomes-james-v-mazzo-to-its-board-of-directors/2478182/LensGen announced the initial closing of a $10 million of the $20 million Bridge Financing and announcd the election of James Mazzo to its Board of Directors.
- Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophieshttps://modernod.com/news/trefoil-therapeutics-begins-first-clinical-trial-of-regenerative-treatment-for-patients-with-corneal-endothelial-dystrophies/2478175/Trefoil Therapeutics announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. The phase 1/2 trial (INTREPID)